A regulatory circuit that involves HR23B and HDAC6 governs the biological response to HDAC inhibitors.
Histone deacetylase (HDAC) is an emergent anticancer target, and HR23B is a biomarker for response to HDAC inhibitors. We show here that HR23B has impacts on two documented effects of HDAC inhibitors; HDAC inhibitors cause apoptosis in cells expressing high levels of HR23B, whereas in cells with low...
Egile Nagusiak: | , , , , , , , , , , |
---|---|
Formatua: | Journal article |
Hizkuntza: | English |
Argitaratua: |
2013
|